Lipid deposits

Lipid deposits represent the pathological accumulation of various lipid species, including triglycerides, cholesterol esters, and phospholipids, within tissues or cellular compartments. These accumulations are central to the pathogenesis of several major diseases, most notably atherosclerosis, where lipid-rich cores develop within the arterial intima, and metabolic dysfunction-associated steatotic liver disease (MASLD), characterized by hepatic triglyceride buildup (PubMed: 30126324, NIH: NBK541036). In the eye, extracellular lipid deposits known as drusen are a hallmark of age-related macular degeneration (PubMed: 26037016). While "lipid deposits" are not a single molecular target, they are the primary endpoint for numerous pharmacological interventions. Drugs such as statins, ezetimibe, and PCSK9 inhibitors work by lowering circulating lipid levels to prevent the formation or promote the regression of these deposits, thereby reducing the risk of cardiovascular events (StatPearls: NBK430910). Additionally, certain localized treatments like deoxycholic acid directly disrupt adipocyte membranes to reduce focal lipid accumulations (PubChem: CID 208). Understanding the composition and stability of these deposits is crucial for developing therapies aimed at plaque stabilization or reversal of steatosis. Monitoring these deposits often involves advanced imaging techniques or systemic lipid biomarkers to assess therapeutic efficacy.

Other names

Lipid accumulationFatty depositsSteatosisLipid dropletsAtherosclerotic plaque lipidsXanthomatous deposits

Reduction of systemic lipid levels through inhibition of synthesis, enhancement of clearance, or reduction of absorption to prevent or reverse tissue accumulation; direct membrane disruption in localized applications.